VEN+G is the only chemo-free regimen designed to stop treatment at 12 months in 1L CLL ¹

• The trial started with an initial cycle of GAZYVA^® (obinutuzumab) followed by the 5-week VENCLEXTA dose ramp-up to help reduce tumor burden (debulk) and decrease the risk of TLS
• After the first treatment cycle of GAZYVA and before the dose ramp-up, patients’ median ALC was reduced by 98% in the CLL14 trial ^1,2*
  *From the median count of 55 x 10⁹ cells/L at baseline to a median count of 1.27 x 10⁹ cells/L at Day 15. Median lymphocyte counts are descriptive in nature and not powered by any type of comparison. Changes in TLS risk status based on ALC reduction were at the discretion of the trial investigators.
  
• Per the trial protocol, tumor burden was assessed based on ALC and lymph node size. The effect of the first GAZYVA treatment cycle on lymph node size was not evaluated ^1,20
• Tumor burden assessments, including radiographic evaluation, and blood chemistry assessments are recommended prior to VENCLEXTA initiation to assess the risk of TLS

IV=intravenous; TLS=tumor lysis syndrome; ALC=absolute lymphocyte count.

Dose information

GAZYVA ¹

• On Cycle 1, Days 1 and 2, administer GAZYVA 100 mg and 900 mg, respectively
• Administer GAZYVA 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle, for a total of 6 cycles
• Refer to the GAZYVA Prescribing Information for recommended dosing information

VENCLEXTA ¹

• On Cycle 1, Day 22, start VENCLEXTA according to the dose ramp-up schedule
• The VENCLEXTA starting dose is 20 mg once daily for 7 days, ramping up weekly to 50 mg, 100 mg, 200 mg, and finally 400 mg once daily
• After completing the ramp-up schedule on Cycle 2, Day 28, patients should continue VENCLEXTA 400 mg once daily from Cycle 3, Day 1 until the last day of Cycle 12

‹ Previous — See 1L Safety